Alembic Pharma today said inspection at its bioequivalence facility in Baroda has been completed by the US health regulator and no observations have been made by it after that.
"This is to inform the exchange that the company's Bioequivalence facility located at Baroda was inspected by the US Food and Drug Administration (US FDA) from March 6, 2017 to March 10, 2017.
"There were no 483s issued by US FDA at the end of the inspection," Alembic Pharmaceuticals said in a BSE filing.
The FDA Form 483 notifies the company's management of objectionable conditions.
Alembic Pharma stock closed 3.55 per cent higher at Rs 623.95 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
